Trung Huynh
Stock Analyst at UBS
(3.29)
# 841
Out of 4,827 analysts
41
Total ratings
50%
Success rate
15.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Neutral | $319 → $315 | $272.05 | +15.79% | 4 | May 2, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,100 → $1,050 | $751.45 | +39.73% | 8 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $768 → $633 | $547.67 | +15.58% | 2 | Apr 30, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $22.97 | +8.84% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $46.88 | +15.19% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $1.21 | +478.51% | 2 | Apr 1, 2025 | |
| INSM Insmed | Maintains: Buy | $105 → $110 | $65.63 | +67.61% | 4 | Mar 6, 2025 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $38 | $4.43 | +757.79% | 1 | Feb 13, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $44 | $19.52 | +125.41% | 1 | Feb 13, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $2.13 | +510.33% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $155.66 | +12.42% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $77.65 | +62.27% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $185.58 | -8.40% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.30 | - | 1 | Mar 23, 2021 |
Amgen
May 2, 2025
Maintains: Neutral
Price Target: $319 → $315
Current: $272.05
Upside: +15.79%
Eli Lilly and Company
May 2, 2025
Maintains: Buy
Price Target: $1,100 → $1,050
Current: $751.45
Upside: +39.73%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $768 → $633
Current: $547.67
Upside: +15.58%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $22.97
Upside: +8.84%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $46.88
Upside: +15.19%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.21
Upside: +478.51%
Insmed
Mar 6, 2025
Maintains: Buy
Price Target: $105 → $110
Current: $65.63
Upside: +67.61%
Jasper Therapeutics
Feb 13, 2025
Initiates: Buy
Price Target: $38
Current: $4.43
Upside: +757.79%
Celldex Therapeutics
Feb 13, 2025
Initiates: Buy
Price Target: $44
Current: $19.52
Upside: +125.41%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $2.13
Upside: +510.33%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $155.66
Upside: +12.42%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $77.65
Upside: +62.27%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $185.58
Upside: -8.40%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $7.30
Upside: -